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 Zürich , Switzerland 
 Risk of Colorectal Carcinoma in Patients with 
Ulcerative Colitis 
 It is well accepted that ulcerative colitis (UC) is associ-
ated with an increased risk of developing colorectal can-
cer (CRC). As the molecular pathways that change during 
the progression from normal epithelia to dysplasia and 
finally cancer are different from sporadic CRC, the term 
‘colitis-associated cancer’ is frequently used. It has been 
estimated in older studies that the risk for this inflam-
mation-associated CRC in UC patients is about 7% at 
20 years of disease  [1–3] , 7–14% at 25 years  [4, 5] and as 
high as 30% after 35 years. In more recent studies, lower 
risks have been reported.
 In a 2001 meta-analysis based on 116 studies with 
54,478 patients, Eaden et al. [6] showed that there is an 
increased risk of cancer in pancolitis as compared to left-
sided colitis ( fig. 1 ). The overall prevalence of CRC in any 
patient with UC was shown to be 3.7%, and 5.4% in pa-
tients with pancolitis  [6] . The cumulative CRC risk for 
any patient with UC was 2% at 10 years, 8% at 20 years 
and 18% at 30 years  [6] ( fig. 1 ). As the background risk in 
the normal population is about 5% during lifetime, this 
means that the risk of developing CRC at 30 years after 
initial diagnosis of UC is three- to fourfold increased at 
least. In ulcerative proctitis, the cancer risk appeared not 
to be increased.
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 Abstract 
 Ulcerative colitis (UC) is a chronic and relapsing inflamma-
tion of the colonic mucosa with variable extension from the 
rectum towards the cecum. The aim of medical treatment is 
to induce and maintain clinical remission. If no remission can 
be achieved, continuous inflammation may repeatedly de-
stroy the epithelial cells. This has to be compensated by epi-
thelial increased proliferation which finally can lead to in-
flammation-associated colorectal cancer (CRC). The risk of 
colitis-associated CRC is increased after a long disease dura-
tion, especially in patients with chronic active disease. This 
risk may be lower if long-lasting mucosal healing can be 
achieved. To detect the development of dysplasia/intraepi-
thelial neoplasia and colitis-associated CRC early, surveil-
lance programs have been installed. However, the evidence 
of success for those surveillance programs is limited. This is 
partially due to problems of detecting precancerous lesions 
in the colonic mucosa during those surveillance programs. 
The specific problems of surveillance programs for the pre-
vention of CRC and specific aspects of patient care in UC are 
reviewed in this article.  Copyright © 2012 S. Karger AG, Basel 
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 In a recent analysis in Denmark, no increased inci-
dence of CRC was found  [7] . Neither the overall cancer 
risk nor the CRC risk was increased in this population-
based cohort in Copenhagen County after a median of 
19 years of follow-up evaluation. This surprising finding, 
however, may be due to the higher rates of colectomy in 
this country and cohort, respectively  [7] . In a large cohort 
of patients with extensive UC (600 patients over a 30-year 
period of observation), Rutter et al. [8] reported cumu-
lative incidences of CRC by colitis duration of 2.5% at 
20 years, 7.6% at 30 years and 10.8% at 40 years. Only 30 
of 600 patients (5%) developed CRC  [8] . A recent Swedish 
analysis including 7,607 patients with UC diagnosed be-
tween 1954 and 1989 investigated frequency of CRC 
through 2004. The study indicated that over the past 
35 years the risk of death from CRC declined markedly 
 [9] ( table 1 ).
 Most recently, Jess et al. [10] performed a meta-analy-
sis on population-based studies. In their analysis, an av-
erage of 1.6% of patients with UC were diagnosed with 
CRC during 14 years of follow-up  [10] . Men with UC had 
a greater risk of CRC as compared to women. In the pop-
ulation-based (unbiased and unselected cohorts), the di-
agnosis of UC increased the risk of CRC 2.4-fold (which 
is clearly lower as compared to the data from Eaden et al. 
[6] ). The direct comparison of the data from Eaden et al. 
[6] and Jess et al. [10] makes the differences obvious: in 
contrast to the above-mentioned cumulative incidences 
of CRC of 2% at 10 years and 8% at 20 years of follow-up 
for any patient with UC, these figures were only 0.4 and 
1.1–5.3%, respectively, in the meta-analysis by Jess et al. 
 [10] . The analysis of nonpopulation-based data derived 
from specialized centers may have introduced some se-
lection bias into the analyses. The lower incidence of CRC 
in UC patients in more recent studies has also been ex-
plained with better control of inflammation and higher 
rates of mucosal healing. As this is hard to prove in clin-
ical studies, it will remain speculative.
 The CRC risk increases with the duration of the dis-
ease and correlates positively with the severity of inflam-
mation and extent of the disease  [6, 11–16] . In fact, there 
is no uniform and general accepted definition of disease 
duration. Onset of symptoms has generally been used as 
starting point for disease duration in the studies that have 
identified this parameter as a risk factor  [17] . Based on the 
meta-analysis by Eaden et al.  [6] , it is assumed that the 
risk for CRC begins to increase 8–10 years after onset of 
inflammation.
 The risk of developing CRC is further increased in pa-
tients with primary sclerosing cholangitis (PSC)  [18–27] .
 Myths and Facts about Surveillance Colonoscopy 
 Generally, it is believed that the colitis-associated 
mortality of CRC can be reduced by surveillance colonos-
copy. Colonoscopic surveillance for dysplasia once a year 
or every 2 years with random biopsies has been advocated 
in many countries and in most guidelines  [16, 17, 28–31] . 
Collins et al. [32] published a Cochrane database system-
atic review in 2006. For their analysis, they focused on 11 
studies attempting to address the impact of surveillance 
colonoscopy on survival of patients with UC. Six of 
these studies were retrospective analyses lacking control 
groups. Three case control studies performed by Karlen 
et al. [33] in 1998 on 4,664 patients, Choi et al. [34] in 1993 
and Lashner et al. [35] in 1990 are discussed in detail. In 
the first study, 2 out of 40 patients that died on CRC had 
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 Fig. 1. Meta-analysis of 116 studies assessing the risk of CRC 
in CU patients  [6] . Cumulative risk of developing CRC: 2% at 
10 years, 8% at 20 years and 18% at 30 years. 
Table 1.  Risk of CRC in 3 population-based Swedish cohorts 
(1954–1989) including 7,607 patients with IBD (198,227 patient-
years)
10 years 20 years 30 years
Pancolitis 1.5 3.8 7.6
UC 1 2.3 5.2
CD 0.5 1.4 2.2
1 96 CRCs were found in 188 patients [9].
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undergone surveillance colonoscopy on at least one occa-
sion as compared with 18 out of 102 of the controls  [33] . 
This difference, however, did not reach statistical signifi-
cance (RR = 0.29, 95% CI: 0.06–1.31)  [33] . In the study by 
Choi et al. [34] , a total of 41 patients developed carcino-
ma: 19 had undergone colonoscopy surveillance and 22 
had not. The 5-year survival rate was 77.2% for cancer of 
the surveillance group and 36.3% for the non-surveil-
lance group (p = 0.026), indicating that the cancers in the 
control group were more advanced as compared to the 
cancers in the surveillance group  [34] . In the study by 
Lashner et al. [35] , 4 out of 91 patients in the surveillance 
group died from CRC as compared to 2 out of 95 patients 
in the non-surveillance group, with no difference seen 
between those groups. It has to be mentioned, however, 
that the benefit of surveillance could have been higher in 
these studies if multiple biopsies had been performed. 
From the data outlined, no clear evidence that surveil-
lance colonoscopy prolongs survival in patients with ex-
tensive colitis can be obtained  [32] . However, it may be 
concluded that cancers are detected at an earlier stage in 
patients who are undergoing surveillance, and that these 
patients have a correspondingly better prognosis  [32] . 
Overall, the Cochrane review is very cautious in its state-
ments pointing to indirect evidence that surveillance is 
likely to be effective in reducing the risk of death from 
inflammatory bowel disease-associated CRC and indi-
rect evidence that it may be acceptably cost-effective  [32] . 
Therefore, also in the ECCO guidelines, the recommen-
dation for surveillance is not strong. In the article by 
 Biancone et al. [17] it is stated – similar to the Cochrane 
review – that surveillance colonoscopy may permit ear-
lier detection of CRC, with a corresponding improved 
prognosis. Further, it is noted that unequivocal evidence 
showing surveillance colonoscopy prolongs survival in 
patients with UC is lacking  [17] .
 When and How Should Surveillance Colonoscopy Be 
Performed? 
 Generally, it is recommended that for surveillance all 
colitis patients should undergo a complete ileocolonos-
copy 8–10 years after the initial symptoms  [17] . As out-
lined above, this recommendation is mainly based on 
meta-analyses that downscale the wide variation in re-
ported CRC risk in different studies  [6, 36] . It should be 
emphasized here that this time-point is referred to the 
initial symptoms and not to the first diagnosis, as patients 
might have had the disease for several years before being 
diagnosed. In patients with extensive colitis, it is recom-
mended that surveillance should start after screening 
colonoscopy (8–10 years after onset of disease) and then 
be performed every other year up to year 20 of disease, 
then annually or annually from 10 years of disease dura-
tion on  [16, 17, 30, 31, 37] .
 In patients with left-sided colitis, also a new staging 
colonoscopy should be performed 8 years after disease 
onset to identify patients with a spreading of inflamma-
tion from left-sided to more extensive disease. Patients 
who still have left-sided colitis should start surveillance 
15 years after first manifestation  [16, 17, 30, 31, 37] . Pa-
tients with extension to pancolitis should have their sur-
veillance colonoscopy every 2 years after the index colo-
noscopy at 8 years (as mentioned above for extensive dis-
ease). In all guidelines the consensus on this strategy is 
strong  [17, 31, 37] despite the lack of robust efficacy data.
 If PSC is present, annual surveillance colonoscopies 
should be started independent of the disease activity and 
extent right after the diagnosis of UC and PSC. In pa-
tients with PSC, the risk of developing a CRC is particu-
larly high and has been reported to occur early (median 
2.9 years) after symptom onset  [19, 20, 23, 38–42] . Despite 
robust data showing a clear advantage of this strategy, it 
is obvious that these patients at high risk for CRC should 
enter a more intensive surveillance program once diag-
nosed.
 The Cochrane review clearly showed that surveillance 
colonoscopy cannot completely abolish the risk of CRC 
in patients with UC  [32] . However, it is likely that those 
CRCs are detected earlier, thus improving the 5-year sur-
vival rate as indicated above. On the other hand, a study 
from the Netherlands indicated that up to 20% of patients 
may have a colitis-associated CRC before the index colo-
noscopy at 8 years after symptom onset  [43] . If the pa-
tients with concomitant PSC are subtracted from this 
group, the frequency of CRC occurring without this risk 
factor before the 8-year margin is still an alarming 10–
15%. The severity of inflammation may be relevant with 
respect to this  [12, 44, 45] . Therefore, it may be justified 
to include patients with chronically active disease in a 
surveillance program earlier. The interval between two 
surveillance colonoscopies should be longer than 2 years, 
as carcinoma might occur in this time-frame interval 
 [46] .
 Despite the fact that ulcerative proctitis might have a 
slightly increased risk of carcinoma  [47] , there is no con-
sensus on regular proctologic examination. In a study by 
Söderlund et al. [9] , the risk of CRC was much greater in 
patients with UC pancolitis (SIR: 5.6; 95% CI: 4.4–7.0) 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
6/
21
/2
01
6 
5:
33
:2
5 
PM
 Inflammatory Bowel Disease Cancer 
Risk, Detection and Surveillance  
Dig Dis 2012;30(suppl 2):48–54 51
when compared with the general population. The stan-
dardized incidence ratio was lower when compared to 
UC patients with proctitis, raising the possibility that UC 
proctitis might be associated with an increased risk of 
CRC  [47] .
 How Should Surveillance Colonoscopies Be 
Performed? 
 Crucial factors for surveillance colonoscopies are on 
one hand the number of biopsies taken and on the other 
hand the time taken for the evaluation of the colon. A 
further important point is with respect to the conditions 
of the colonoscopy, i.e. whether the cleansing of the gut 
has been done successfully  [48] . If the conditions of the 
colonoscopy are not perfect due to feces still being pres-
ent, the colonoscopy should be repeated  [48] . Further, it 
appears to be important that the colonoscopy is done 
during a remission phase of the colitis as the histomor-
phological discrimination of inflamed and neoplastic 
changes is difficult. Low-grade dysplasia may be missed 
as inflamed mucosa is present or, on the other hand, in-
flamed mucosa may be misinterpreted as dysplastic mu-
cosa  [49] . Of course, the general aim of surveillance colo-
noscopies is to detect neoplasias with high sensitivity and 
specificity. Macroscopic evaluation of the gut is therefore 
very helpful  [50, 51] . It has even been stated that upon ex-
cellent preparation most lesions will be macroscopically 
visible  [50, 52] . If the mucosa is inflamed, the macroscop-
ic evaluation is difficult  [49] .
 Targeted biopsies should be taken from all endoscopi-
cally suspect lesions  [50–52] . In addition, blind and non-
targeted biopsies should be taken every 4 cm in all quad-
rants as up to 20% of dysplastic lesions may not be visible 
macroscopically. Mathematical modeling was done by 
Rubin et al. [53] indicating that 34 random biopsies will 
result in a 90% CI to detect CRC or high-grade dysplasia, 
64 biopsies will be necessary for a 95% probability of de-
tection. Despite the fact that this is only a model based on 
a questionable basis and that the evidence is weak, similar 
numbers for random biopsies during surveillance colo-
noscopy can now be found in a number of guidelines  [31, 
37] . To achieve a 90% security for the detection of dyspla-
sia/neoplastic lesions, it is recommended that 4 biopsies 
are taken every 10 cm. In 2003, Kiesslich et al. [54] found 
only 2 intraepithelial neoplasias in 598 random biopsies, 
and in 2004 Rutter et al. [55] did not detect any intraepi-
thelial neoplasias in 2,906 random biopsies. As with the 
new techniques of high-resolution endoscopy, lesions 
may be visible much better than in former eras  [50, 52] ; 
however, this point is still a matter of discussion. In real-
ity, the number of random biopsies taken during surveil-
lance colonoscopy in UC patients is usually much lower 
 [29] .
 As an alternative, chromoendoscopy with targeted bi-
opsies in all suspect areas may be recommended  [55–58] . 
The advantages of chromoendoscopy were recently con-
firmed in a multicenter study which detected more in-
traepithelial neoplasia as compared to conventional colo-
noscopy  [59] . However, it should be kept in mind that 
methylene blue, which is frequently recommended for 
chromoendoscopy, may cause DNA damage and contrib-
ute to CRC risk  [60–62] . Therefore, indigo carmine seems 
to be the better alternative for chromoendoscopy  [55, 60, 
63] . The other techniques that have been investigated in 
recent years should not be used as stand-alone strategies.
 A number of studies in recent years could demonstrate 
that the higher number of intraepithelial neoplasias can 
be detected with high-resolution endoscopy  [64] . Irregu-
lar mucosa structures or elevated areas of the mucosa 
might be detected  [65, 66] . Presently, however, the pub-
lished data are not sufficient to completely omit the rec-
ommendation for random biopsies. As a potential re-
placement of chromoendoscopy, virtual chromoendos-
copy techniques such as NBI, FICE or I-SCAN have been 
recommended; however, the data published so far are in-
conclusive  [67–70] .
 What to Do if Dysplasia/Intraepithelial Neoplasia 
Has Been Found? 
 If an intraepithelial neoplasia is detected, there should 
be an external and independent second opinion by a pa-
thologist  [16, 17, 30, 31, 37] . The presence of a low-grade 
intraepithelial neoplasia should be reinvestigated by colo-
noscopy control after an increase of anti-inflammatory 
therapy within 3 months.
 The grading of the intraepithelial neoplasias is very 
important for the CRC risk in patients with UC. When a 
patient undergoes colectomy due to CRC, random biop-
sies in the colectomy specimen detect intraepithelial neo-
plasia in up to 74%  [71] . This indicates that there may be 
several additional neoplasias in UC colon that have al-
ready developed CRC at one location. A meta-analysis 
has shown that in low-grade intraepithelial neoplasias 
and low-grade dysplasia, the risk for CRC is at least nine-
fold  [72] . Therefore, the detection of low-grade dysplasia 
and low-grade intraepithelial neoplasias has important 
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consequences for further treatment. However, there is a 
high interobserver variability among pathologists  [73] . 
The variability is especially high for low-grade dysplasia 
 [73] . Due to the therapeutic consequences, therefore, an 
independent second opinion is mandatory. In the meta-
analysis by Thomas et al. [72] based on 20 studies with 
508 patients with low-grade dysplasia, an up to 12-fold 
risk of developing advanced lesions such as high-grade 
dysplasia or CRC as compared to patients without low-
grade dysplasia was found  [72] . The positive protective 
value for low-grade dysplasia including DALM for con-
current advanced lesions was 37%. The positive protec-
tive value for low-grade dysplasia in the presence of a 
DALM for concurrent advanced lesions was 41%  [72] ! If 
a second external pathologist confirms the diagnosis of 
low-grade dysplasia or low-grade intraepithelial neopla-
sia, the patient should be informed about his risk and 
proctocolectomy should be recommended. As an alter-
native, a tight surveillance colonoscopy program every 
3 months might be acceptable. Adenoma-associated dys-
plasia, however, has to be treated differently. A clear ade-
noma-like lesion with intraepithelial neoplasia, which is 
classified as adenoma-associated dysplasia by the pathol-
ogist, should be resected endoscopically.
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